Tango Therapeutics, Inc. announced changes to its Board of Directors. John Ketchum has been appointed to join the Company?s Board of Directors. In addition, current director Aaron Davis has stepped down from his position.

Both changes are effective immediately. John Ketchum has more than 30 years of experience in the biopharmaceutical industry, including more than 20 years at Novartis. During this time, he was a member of the Novartis Oncology Executive Committee and European Pharma organization Board Level International Committee, and held roles spanning pre-launch commercialization, clinical development, product launch and marketing, and general management on six continents.